OR11H12

Across TCGA pan-cancer cohorts, OR11H12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR11H12 data layer compared with 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OR11H12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR11H12 expression acts as an unfavorable survival marker.

STAD, COAD, and LAML are the cancer types where OR11H12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.184	0.730	.001	33	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	9	view →
LAML	DFS	Median	All	0.028	0.572	<.001	6	view →
LUSC	OS	Median	III,IV	0.174	0.570	.031	6	view →
SKCM	DFS	Median	II,III,IV	0.015	0.709	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OR11H12–STAD (OS)

Open the STAD breakdown →